Nu.Q
Accessible and Affordable Canine Cancer Screen and Monitor Test
In-clinic test coming soon, exclusively on Element i+
-
Peer Reviewed Evidence
Methodology backed by studies on canine lymphoma, canine hemangiosarcoma, and other common canine cancers.
-
Early Cancer Detection
Proven ability to detect all stages of canine lymphosarcoma and hemangiosarcoma.
-
High Detection Rate
Detects 76% of systemic canine cancers at 97% specificity.
-
Small Sample Size
Only 1 mL of EDTA-plasma needed for all canine breeds and sizes.
-
Accessible and Affordable
Now cancer screening is easily available at an affordable cost for you and your clients.
-
State-of-the-Art Technology
Measures levels of nucleosomes circulating in the patient’s blood.
Stop overpaying for in-clinic blood testing and analysis.
Heska’s Reset program provides veterinarians with accurate, better and faster blood testing and analysis up to 40% less cost than with other competitive in-house diagnostic laboratory services.
The Nu.Q Canine Cancer Screen and Monitor measures nucleosomes to provide clinicians with actionable results.
Effective Cancer Screening
Nucleosome measurement provides clinicians reasonable levels of suspicion for active neoplasia.
Early Detection, Earlier Treatment
Early detection leads to more comprehensive and effective treatment for your patient.
High Detection Rate
Detects 76% of systemic canine cancers at 97% specificity.
Technical Details & Downloads
Canine Cancer Screening in Your Practice
Approximately 6 million dogs are diagnosed with cancer in the United States each year. Early detection can mean better treatment and outcomes for your patients. In partnership with Volition Veterinary, Heska is proud to offer the The Nu.Q® Canine Cancer Screen and Monitor Test. Nearly 50% of dogs over 10 will develop cancer. These diagnoses are often unexpected and debilitating for patients and pet parents alike. Cancer screening with the The Nu.Q® Canine Cancer Screen and Monitor Test aids in early detection, leading to more comprehensive and effective treatment.
Cancer screening with Nu.Q® provides the opportunity to detect cancer early. Studies have shown that measuring nucleosomes in blood has the potential to detect multiple stages of common canine cancers, such as lymphoma and hemangiosarcoma.
Intended for screening dogs 7 years and older, or predisposed individuals and breeds, Nu.Q® Vet Cancer Screening allows veterinary professionals the chance to catch cancer early and provide a higher level of care.
How Does it Work?
During cell death, chromatin is fragmented into nucleosomes, which are released into the bloodstream. Cancer is usually characterized by high levels of cellular turnover, in turn leading to higher levels of nucleosomes circulating in blood. The Nu.Q® Canine Cancer Screen and Monitor Test measures these nucleosomes to provide clinicians with actionable results.
Empirical Evidence
- 77% of Canine Lymphosarcoma Found – detection of all 5 stages
- 82% of Canine Hemangiosarcoma Found – detection of all 3 stages
- Multi-cancer Study Results: Nu.Q Vet Cancer Screening Test detects 76% of Systemic Cancers at 97% Specificity
Watch the Recorded Webinar: A Look to the Future of Canine Cancer Diagnostics
Learn about the science behind cancer screening using nucleosomic quantification (Nu.Q®) technology, and the importance of implementing cancer screening into wellness visits.
Heska Support Teams are Here for You
We’re Available When You Need Us
Rest assured that when you need help, have questions, or have difficulties, we have you covered.
